Published Date: 08 Jan 2025
The incidence of in situ breast cancer has decreased since 2009, consistent with decreasing use of mammography in association with the 2009 U.S. Preventive Services Task Force (USPSTF) guideline change, according to a study ...
Read Full NewsResearchers conducted a retrospective analysis of patients with newly diagnosed NPM1-mutated AML treated with high- or low-intensity regimens.
Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.
1.
Prostate cancer Q&A: Improving detection and reducing overtreatment
2.
FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting
3.
A retrospective study examined the role of CA 19-9 and CEA in duodenal adenocarcinoma prognosis.
4.
Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL
5.
New imaging technique identifies glioblastoma patients who would benefit from immunotherapy
1.
Understanding Villous Adenoma: Causes, Symptoms, and Treatments
2.
Unlocking the Potential of Leukemia Treatment: A New Hope for Patients
3.
Generative AI for Adaptive Oncology Trial Design
4.
The Future is Now: Navigating the Precision Revolution in Oncology Treatment
5.
Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
From Guidelines to Practice: Hematology
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation